Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐Analysis
- 12 June 2011
- journal article
- review article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 30 (4), 217-226
- https://doi.org/10.1111/j.1755-5922.2011.00277.x
Abstract
Background Xanthine oxidase inhibition (XOI) reduces oxidative stress in the vasculature. Moreover it reduces uric acid levels, a risk factor for the development of cardiovascular disease. As such, XOI holds a potentially dual mechanism for the treatment of cardiovascular disease. Aims Through systematic review, we sought to clarify the extent of available evidence that has evaluated the effect of XOI upon clinical or surrogate markers of cardiovascular disease and function in humans. Methods A systematic search strategy was used to interrogate the Ovid Medline (1950June Week 4 2010) and Embase (19802010 Week 25) databases, to identify relevant studies. Meta-analysis was planned for frequently studied endpoints. Results Thirty-eight publications (reporting 40 studies) were identified. There was heterogeneity between studies in all aspects of study design, including the outcome measures of interest. Prospective assessment of surrogate markers predominated. Combined meta-analysis was feasible for three outcome parameters, with favorable modifications in each following xanthine oxidase inhibition: brachial artery flow mediated dilatation (five studies: XOI n = 75, control n = 69) increased by 2.50% (95% CI, 0.154.84); forearm blood flow responses to acetylcholine infusion (five studies: XOI n = 74, control n = 74) increased by 68.80 (95% CI, 18.70118.90; percent change relative to noninfused control arm); circulating markers of oxidative stress (malondialdehyde, six studies: XOI n = 78, control n = 68) reduced by 0.56 nmol/mL (95% CI, 0.260.87). Conclusions XOI improves endothelial function and circulating markers of oxidative stress in patients with, or at risk of, cardiovascular disease. Large prospective studies examining definitive end points are lacking but now appear indicated.Keywords
This publication has 59 references indexed in Scilit:
- Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trialThe Lancet, 2010
- The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trialBritish Journal of Clinical Pharmacology, 2009
- Allopurinol and Nitric Oxide Activity in the Cerebral Circulation of Those With DiabetesDiabetes Care, 2009
- Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic StrokeStroke, 2008
- Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential HypertensionJAMA, 2008
- Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?British Journal of Clinical Pharmacology, 2006
- Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathyFree Radical Biology & Medicine, 2006
- Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular riskThe American Journal of Cardiology, 2004
- Xanthine Oxidase Inhibition With Oxypurinol Improves Endothelial Vasodilator Function in Hypercholesterolemic but Not in Hypertensive PatientsHypertension, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996